Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Clinical Trials

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Phase 2

Not yet recruiting

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Graft Versus Host Disease
Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Drug: Melphalan
Procedure: Multigated Acquisition Scan
Other: Questionnaire Administration
Drug: Tacrolimus
Biological: Vedolizumab

First Posted Date: 2025-02-07

Last Posted Date: 2025-02-07

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 35

Registration Number: NCT06815003

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Hematologic Diseases

Interventions: Drug: Busulfan (Busulfex)
Drug: Cyclophosphamide (CTX)
Drug: Fludarabine (Fludara)
Drug: Semustine (MeCCNU)

First Posted Date: 2025-02-05

Last Posted Date: 2025-02-05

Lead Sponsor: He Huang

Target Recruit Count: 29

Registration Number: NCT06809699

Locations: 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Hematologic Disease

Interventions: Drug: Busulfan (Busulfex)
Drug: Cyclophosphamide (CTX)
Drug: Fludarabine (Fludara)
Drug: Semustine (MeccNU)

First Posted Date: 2025-02-05

Last Posted Date: 2025-02-05

Lead Sponsor: He Huang

Target Recruit Count: 29

Registration Number: NCT06809712

Locations: 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Phase 2

Recruiting

Conditions: Hematologic Malignancies

Interventions: Drug: Drugs Cyclophosphamide
Drug: Fludarabine
Drug: Thiotepa
Drug: Tacrolimus
Drug: Mycophenolate mofetil

First Posted Date: 2025-02-04

Last Posted Date: 2025-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT06807606

Locations: 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients with High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia, Relapsed, Adult
Acute Myeloid Leukemia Refractory
Chronic Myeloid Leukemia - Accelerated Phase
Myelodysplastic Syndromes

Interventions: Radiation: Intensity modulated total marrow irradiation
Drug: Cyclophosphamide (CTX)
Drug: Fludarabine (Fludara)
Drug: Busulfan (conditioning for ALLO Transplant)

First Posted Date: 2025-01-31

Last Posted Date: 2025-02-04

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 38

Registration Number: NCT06802315

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States

A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Biological: NK042
Drug: Fludarabine (FLU)
Drug: Cyclophosphamide (CTX)

First Posted Date: 2025-01-14

Last Posted Date: 2025-02-11

Lead Sponsor: Shanghai NK Cell Technology Co., LTD

Target Recruit Count: 76

Registration Number: NCT06773091

Locations: 🇨🇳
Peking University Cancer Hospital, Beijing, China

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Early Phase 1

Recruiting

Conditions: Relapsed/refractory Lymphoma
Relapsed/Refractory Leukemia

Interventions: Biological: anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2025-01-03

Last Posted Date: 2025-01-03

Lead Sponsor: Affiliated Hospital of Nantong University

Target Recruit Count: 9

Registration Number: NCT06756321

Locations: 🇨🇳
Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Phase 2

Recruiting

Conditions: Aplastic Anemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Transplantation
Procedure: Computed Tomography
Drug: Cyclosporine
Drug: Fludarabine
Drug: Granulocyte Colony-Stimulating Factor
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Ruxolitinib
Drug: Sirolimus
Radiation: Total-Body Irradiation
Procedure: Multigated Acquisition Scan
Procedure: Echocardiography